|
ES2456325T3
(es)
|
2003-11-06 |
2014-04-22 |
Seattle Genetics, Inc. |
Compuestos de monometilvalina capaces de conjugación con ligandos
|
|
US8288352B2
(en)
|
2004-11-12 |
2012-10-16 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
EP2609932B1
(en)
|
2006-12-01 |
2022-02-02 |
Seagen Inc. |
Variant target binding agents and uses thereof
|
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
SI2474557T1
(sl)
|
2007-07-16 |
2014-12-31 |
Genentech, Inc. |
Protiteles proti CD79b in imunokonjugati in postopki za uporabo
|
|
CL2008002083A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
|
US7968687B2
(en)
|
2007-10-19 |
2011-06-28 |
Seattle Genetics, Inc. |
CD19 binding agents and uses thereof
|
|
RS54883B1
(sr)
|
2008-01-31 |
2016-10-31 |
Genentech Inc |
Anti-cd79b antitela i imunokonjugati i metode upotrebe
|
|
EP2282773B2
(en)
|
2008-05-02 |
2025-03-05 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
PH12012500665B1
(en)
|
2009-10-23 |
2019-10-30 |
Amgen British Columbia |
Anti-gcc antibody molecules and related compositions and methods
|
|
US8609092B2
(en)
|
2010-02-08 |
2013-12-17 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
|
PT2542576T
(pt)
|
2010-03-02 |
2016-07-14 |
Seattle Genetics Inc |
Métodos para rastreio de anticorpos
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
PL2608796T3
(pl)
|
2010-08-05 |
2019-04-30 |
Seattle Genetics Inc |
Hamowanie fukozylacji białka w warunkach in vivo za pomocą analogów fukozy
|
|
WO2012046745A1
(ja)
*
|
2010-10-04 |
2012-04-12 |
独立行政法人理化学研究所 |
Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
|
|
EP2629801B3
(en)
|
2010-10-22 |
2019-11-27 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
WO2012085845A1
(en)
|
2010-12-23 |
2012-06-28 |
Eulitha A.G. |
System and method for production of nanostructures over large areas
|
|
ES2623912T3
(es)
*
|
2010-12-23 |
2017-07-12 |
Janssen Biotech, Inc. |
Mutantes FC de anticuerpo activo resistente a proteasa
|
|
KR101529810B1
(ko)
*
|
2011-04-01 |
2015-06-26 |
와이어쓰 엘엘씨 |
항체-약물 접합체
|
|
EP2717916B1
(en)
|
2011-06-10 |
2017-03-08 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US10300140B2
(en)
|
2011-07-28 |
2019-05-28 |
I2 Pharmaceuticals, Inc. |
Sur-binding proteins against ERBB3
|
|
SMT202200160T1
(it)
|
2011-08-16 |
2022-05-12 |
Morphosys Ag |
Terapia in combinazione con un anticorpo anti-cd19 e un analogo delle purine
|
|
WO2013024097A1
(en)
|
2011-08-16 |
2013-02-21 |
Morphosys Ag |
Combination therapy with an anti - cd19 antibody and a nitrogen mustard
|
|
CN102343083A
(zh)
*
|
2011-10-17 |
2012-02-08 |
中国科学院成都生物研究所 |
一种抗病毒的组合药物
|
|
WO2013067581A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Children's Cancer Institute Australia for Medical Research |
Cancer treatment
|
|
ES2710916T3
(es)
|
2011-12-22 |
2019-04-29 |
I2 Pharmaceuticals Inc |
Proteínas de unión sustitutas
|
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
|
JP6602012B2
(ja)
|
2012-02-10 |
2019-11-06 |
シアトル ジェネティクス インコーポレーテッド |
Ｃｄ３０＋癌の検出と治療
|
|
KR102144069B1
(ko)
|
2012-05-15 |
2020-08-13 |
시애틀 지네틱스, 인크. |
자가-안정화 링커 접합체
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
SG11201408679XA
(en)
|
2012-06-26 |
2015-01-29 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
|
CN104507537A
(zh)
*
|
2012-07-13 |
2015-04-08 |
宾夕法尼亚大学董事会 |
用于调节car t细胞的组合物和方法
|
|
ES2528892T3
(es)
|
2012-07-30 |
2015-02-13 |
Nbe-Therapeutics Llc |
Identificación mediada por trasposición de proteínas de unión o funcionales específicas
|
|
CA2882725C
(en)
|
2012-08-23 |
2021-03-09 |
Regents Of The University Of Minnesota |
Treatment of sickle cell disease and inflammatory conditions
|
|
WO2014031174A1
(en)
|
2012-08-24 |
2014-02-27 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
|
RS58921B1
(sr)
|
2012-10-12 |
2019-08-30 |
Medimmune Ltd |
Pirolobenzodiazepini i njihovi konjugati
|
|
NO2789793T3
(enExample)
*
|
2012-10-24 |
2018-01-27 |
|
|
|
IN2015DN02349A
(enExample)
*
|
2012-10-24 |
2015-08-28 |
Polytherics Ltd |
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
AU2013364043B2
(en)
|
2012-12-21 |
2018-01-04 |
Seagen Inc. |
Anti-NTB-A antibodies and related compositions and methods
|
|
KR102066319B1
(ko)
|
2013-03-13 |
2020-01-14 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨쥬게이트
|
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
|
EP2970491A4
(en)
*
|
2013-03-15 |
2016-11-23 |
Alper Biotech Llc |
MONOCLONAL ANTIBODIES AGAINST EGFR AND USES THEREOF
|
|
TWI654206B
(zh)
*
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
US11491154B2
(en)
|
2013-04-08 |
2022-11-08 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
RS63798B1
(sr)
*
|
2013-05-13 |
2022-12-30 |
Cellectis |
Cd19 specifični himerni antigenski receptor i njegove primene
|
|
JP6747971B2
(ja)
|
2013-10-15 |
2020-08-26 |
シアトル ジェネティックス， インコーポレイテッド |
改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー
|
|
EP3082877B1
(en)
|
2013-12-17 |
2019-08-28 |
Novartis AG |
Cytotoxic peptides and conjugates thereof
|
|
EP4190809A1
(en)
|
2014-02-11 |
2023-06-07 |
Seagen Inc. |
Selective reduction of proteins
|
|
ES2885686T3
(es)
|
2014-02-17 |
2021-12-15 |
Seagen Inc |
Conjugados anticuerpo-fármaco hidrófilos
|
|
CN111499753B
(zh)
|
2014-03-03 |
2022-10-21 |
高雄医学大学 |
双功能抗体及其用途
|
|
WO2015143123A2
(en)
|
2014-03-19 |
2015-09-24 |
Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation |
Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
|
|
EA201692002A1
(ru)
*
|
2014-04-07 |
2017-01-30 |
Сиэтл Дженетикс, Инк. |
Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
|
|
CN106170300A
(zh)
*
|
2014-04-08 |
2016-11-30 |
西雅图基因公司 |
Cd19‑抗体药物偶联物的优化给药
|
|
WO2015189791A1
(en)
|
2014-06-13 |
2015-12-17 |
Novartis Ag |
Auristatin derivatives and conjugates thereof
|
|
ES2785551T3
(es)
|
2014-06-30 |
2020-10-07 |
Glykos Finland Oy |
Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
|
|
CA2957964A1
(en)
|
2014-09-03 |
2016-03-10 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
|
AU2015315007C1
(en)
|
2014-09-11 |
2021-06-03 |
Seagen Inc. |
Targeted delivery of tertiary amine-containing drug substances
|
|
RS60349B8
(sr)
|
2014-09-23 |
2022-10-31 |
Hoffmann La Roche |
Postupak upotrebe anti-cd79b imunokonjugata
|
|
CN107484416A
(zh)
*
|
2014-09-26 |
2017-12-15 |
宏观基因有限公司 |
能够结合cd19和cd3的双特异性单价双抗体及其用途
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
HK1247619A1
(zh)
*
|
2015-02-12 |
2018-09-28 |
Seattle Genetics, Inc. |
使用抗 dc 19抗体–药物共轭物及长春新硷的联合治疗
|
|
MX382582B
(es)
|
2015-03-18 |
2025-03-13 |
Seagen Inc |
Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
|
|
HK1251152B
(en)
|
2015-05-26 |
2020-04-24 |
Morphosys Ag |
Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
|
|
WO2015151079A2
(en)
*
|
2015-06-20 |
2015-10-08 |
Hangzhou Dac Biotech Co, Ltd |
Auristatin analogues and their conjugates with cell-binding molecules
|
|
ES2955961T3
(es)
|
2015-06-30 |
2023-12-11 |
Seagen Inc |
Anticuerpos anti-ntb-a y composiciones y métodos relacionados
|
|
EP3337506B1
(en)
|
2015-08-21 |
2021-07-21 |
MorphoSys AG |
Combinations and uses thereof
|
|
CN114814055B
(zh)
*
|
2015-09-08 |
2025-03-18 |
沃特世科技公司 |
用于分析抗体-药物缀合物的多维色谱方法
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
PL3359576T3
(pl)
|
2015-10-08 |
2025-04-14 |
Zymeworks Bc Inc. |
Konstrukty polipeptydowe wiążące antygen zawierające łańcuchy lekkie kappa i lambda oraz ich zastosowania
|
|
IL258491B2
(en)
|
2015-10-16 |
2023-09-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a particular lineage
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
US11229708B2
(en)
|
2015-12-04 |
2022-01-25 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
US20170233484A1
(en)
|
2016-02-17 |
2017-08-17 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
EP3442584B1
(en)
|
2016-03-15 |
2021-07-28 |
Seagen Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
|
|
JP7208010B2
(ja)
*
|
2016-03-29 |
2023-01-18 |
ユニバーシティ オブ サザン カリフォルニア |
癌を標的とするキメラ抗原受容体
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
ES2878156T3
(es)
|
2016-05-30 |
2021-11-18 |
Morphosys Ag |
Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
|
|
MA45450B1
(fr)
|
2016-06-27 |
2021-04-30 |
Morphosys Ag |
Formulations d'anticorps anti-cd19
|
|
TWI767915B
(zh)
|
2016-06-27 |
2022-06-21 |
加州大學董事會 |
Ror-1與btk拮抗劑的組合
|
|
EP3487525A4
(en)
*
|
2016-07-22 |
2020-03-18 |
Seattle Genetics, Inc. |
COMBINATION THERAPY WITH CD19-ADC AND RCHP
|
|
CN109562152B
(zh)
|
2016-08-09 |
2024-04-02 |
西雅图基因公司 |
含有具有改善的生理化学性质的自稳定性接头的药物缀合物
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
US20200023072A1
(en)
|
2016-10-11 |
2020-01-23 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
KR20190074292A
(ko)
|
2016-10-18 |
2019-06-27 |
시애틀 지네틱스, 인크. |
니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
|
|
JP7094950B2
(ja)
|
2016-10-28 |
2022-07-04 |
モルフォシス・アーゲー |
抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
|
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
CN116672463A
(zh)
*
|
2017-02-17 |
2023-09-01 |
浙江特瑞思药业股份有限公司 |
靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途
|
|
KR102697394B1
(ko)
|
2017-02-28 |
2024-08-20 |
씨젠 인크. |
컨쥬게이션을 위한 시스테인 변이된 항체
|
|
EP3589291A4
(en)
*
|
2017-02-28 |
2020-11-25 |
Vor Biopharma, Inc. |
COMPOSITIONS AND METHODS OF INHIBITION OF LINE-SPECIFIC PROTEINS
|
|
CN110430901B
(zh)
|
2017-03-24 |
2024-08-16 |
西雅图基因公司 |
制备葡糖苷酸药物-接头及其中间体的方法
|
|
AU2018256436B2
(en)
|
2017-04-19 |
2024-12-05 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
CN110799217A
(zh)
|
2017-04-27 |
2020-02-14 |
西雅图基因公司 |
季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
WO2018222675A1
(en)
|
2017-05-30 |
2018-12-06 |
The Board Of Regents Of The University Of Oklahoma |
Anti-doublecortin-like kinase 1 antibodies and methods of use
|
|
DK3630177T5
(da)
|
2017-05-31 |
2024-09-02 |
Morphosys Ag |
Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling
|
|
EP3652206A1
(en)
|
2017-07-10 |
2020-05-20 |
International-Drug-Development-Biotech |
Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics
|
|
FI3666787T3
(fi)
|
2017-08-10 |
2024-03-15 |
Sumitomo Pharma Co Ltd |
Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja
|
|
US12018093B2
(en)
|
2017-08-10 |
2024-06-25 |
Sumitomo Pharma Co., Ltd. |
Hemiasterlin derivatives and antibody-drug conjugates including same
|
|
CN115819588A
(zh)
*
|
2017-09-21 |
2023-03-21 |
上海药明生物技术有限公司 |
新型抗cd19抗体
|
|
JP7185696B2
(ja)
|
2017-09-22 |
2022-12-07 |
ウーシー バイオロジクス アイルランド リミテッド |
新規な二重特異性ｃｄ３／ｃｄ１９ポリペプチド複合体相互参照
|
|
CA3115374A1
(en)
|
2017-10-12 |
2019-04-18 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
US11180552B2
(en)
|
2017-12-01 |
2021-11-23 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
|
KR20200090838A
(ko)
|
2017-12-01 |
2020-07-29 |
시애틀 지네틱스, 인크. |
유방암 치료를 위한 인간화된 항-liv1 항체
|
|
EP3728330A4
(en)
*
|
2017-12-23 |
2021-12-08 |
Uwell Biopharma Inc. |
PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS
|
|
EP3735252A4
(en)
*
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
CN112189020A
(zh)
|
2018-03-23 |
2021-01-05 |
西雅图基因公司 |
包含微管蛋白破坏剂的抗体药物缀合物用于治疗实体瘤的用途
|
|
KR20210016562A
(ko)
|
2018-05-23 |
2021-02-16 |
에이디씨 테라퓨틱스 에스에이 |
분자 애쥬번트
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
KR20210042120A
(ko)
|
2018-08-06 |
2021-04-16 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트와 튜불린 저해제의 조합
|
|
JP2022520138A
(ja)
|
2018-08-28 |
2022-03-29 |
ブイオーアール バイオファーマ インコーポレーテッド |
遺伝子操作された造血幹細胞およびそれらの使用
|
|
CN111138542B
(zh)
*
|
2018-11-01 |
2022-09-23 |
山东新时代药业有限公司 |
双特异性抗体及其用途
|
|
EP3917966A4
(en)
*
|
2019-02-01 |
2022-10-19 |
Memorial Sloan Kettering Cancer Center |
UPAR-TARGETING SENOLYTIC CAR-T CELLS, CELL SURFACE AND SECRETED SENSCENCE BIOMARKERS
|
|
KR20210125511A
(ko)
|
2019-02-05 |
2021-10-18 |
씨젠 인크. |
항-cd228 항체 및 항체-약물 컨쥬게이트
|
|
JP7479302B2
(ja)
*
|
2019-02-13 |
2024-05-08 |
住友ファーマ株式会社 |
ヘミアスタリン誘導体とその抗体薬物複合体
|
|
CA3127312A1
(en)
|
2019-02-13 |
2020-08-20 |
Sumitomo Dainippon Pharma Co., Ltd. |
Hemiasterlin derivative having cysteine residue
|
|
JP7560255B2
(ja)
*
|
2019-02-13 |
2024-10-02 |
住友ファーマ株式会社 |
ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
|
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
WO2020225196A1
(en)
|
2019-05-03 |
2020-11-12 |
Morphosys Ag |
Anti-cd19 therapy in patients having a limited number of nk cells
|
|
CN110128551A
(zh)
*
|
2019-06-05 |
2019-08-16 |
上海科弈药业科技有限公司 |
一种针对cd19+肿瘤的多功能融合蛋白及其应用
|
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
AR119097A1
(es)
|
2019-06-05 |
2021-11-24 |
Seattle Genetics Inc |
Métodos de purificación de anticuerpos enmascarados
|
|
KR20220035486A
(ko)
|
2019-07-22 |
2022-03-22 |
씨젠 인크. |
암 치료를 위한 인간화 항-liv1 항체
|
|
EP4038194A1
(en)
|
2019-10-04 |
2022-08-10 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
KR20220075351A
(ko)
|
2019-10-04 |
2022-06-08 |
씨젠 인크. |
항-pd-l1 항체 및 항체-약물 접합체
|
|
IL317199A
(en)
|
2019-10-31 |
2025-01-01 |
Morphosys Ag |
Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
|
|
IL292213A
(en)
|
2019-10-31 |
2022-06-01 |
Morphosys Ag |
Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cells
|
|
WO2021119531A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Cullinan Management, Inc. |
Anti-serum albumin antibodies
|
|
EP4073122A4
(en)
*
|
2019-12-11 |
2024-03-27 |
Cullinan Oncology, Inc. |
ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS
|
|
AU2021231712A1
(en)
*
|
2020-03-03 |
2022-10-06 |
Systimmune, Inc. |
Anti-CD19 antibodies and methods of using and making thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CN115955980A
(zh)
|
2020-04-10 |
2023-04-11 |
思进公司 |
电荷可变接头
|
|
KR20230030636A
(ko)
|
2020-06-22 |
2023-03-06 |
모르포시스 아게 |
항-CD19 항체, 및 SIRPα-CD47 선천성 면역 체크포인트를 차단하는 폴리펩티드를 포함하는 항-종양 조합 요법
|
|
KR20230042518A
(ko)
|
2020-08-04 |
2023-03-28 |
씨젠 인크. |
항-cd228 항체 및 항체-약물 컨쥬게이트
|
|
CA3197158A1
(en)
|
2020-09-28 |
2022-03-31 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
|
US20240262907A1
(en)
|
2020-10-06 |
2024-08-08 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
MX2023004941A
(es)
|
2020-11-08 |
2023-07-12 |
Seagen Inc |
Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
|
|
TW202237184A
(zh)
|
2020-12-04 |
2022-10-01 |
德商莫菲西斯公司 |
抗cd19組合療法
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US12030888B2
(en)
|
2021-02-24 |
2024-07-09 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
KR20230158005A
(ko)
|
2021-03-18 |
2023-11-17 |
씨젠 인크. |
생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
|
|
WO2022236047A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Viela Bio, Inc. |
Use of an anti-cd19 antibody to treat myasthenia gravis
|
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
|
US20240376200A1
(en)
|
2021-09-24 |
2024-11-14 |
Seagen Inc. |
Improved Antibody Masking Domains
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
KR20240095442A
(ko)
|
2021-11-03 |
2024-06-25 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
항체의 특이적 접합
|
|
WO2023108102A1
(en)
*
|
2021-12-10 |
2023-06-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Anti-lcn-2 antibodies as a treatment for eye disorders
|
|
CN119278055A
(zh)
|
2022-03-17 |
2025-01-07 |
思进公司 |
喜树碱缀合物
|
|
CA3258083A1
(en)
|
2022-06-16 |
2023-12-21 |
Abbvie Biotherapeutics Inc |
ANTI-CD19 DRUG-ANTIBODY CONJUGATES
|
|
AU2023326589A1
(en)
|
2022-08-17 |
2025-02-20 |
Incyte Corporation |
Therapy comprising anti-cd19 antibody and ezh2 modulators
|
|
AU2023347922A1
(en)
|
2022-09-21 |
2025-03-20 |
Seagen Inc. |
Antibodies that bind cd228
|
|
AU2023372538A1
(en)
|
2022-11-03 |
2025-05-01 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
EP4634227A1
(en)
|
2022-12-13 |
2025-10-22 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
TW202434311A
(zh)
|
2023-02-09 |
2024-09-01 |
英屬開曼群島商百濟神州有限公司 |
自穩定連接子軛合物
|
|
TW202438114A
(zh)
|
2023-03-23 |
2024-10-01 |
瑞士商百濟神州瑞士有限責任公司 |
生物活性結合物、其製備方法及其用途
|
|
CN120641113A
(zh)
|
2023-03-31 |
2025-09-12 |
西比曼生物科技集团 |
靶向cd20和bcma的双特异性嵌合抗原受体
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025157132A1
(en)
|
2024-01-23 |
2025-07-31 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
|
|
WO2025163468A1
(en)
|
2024-01-30 |
2025-08-07 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|